NCT06489860

SARS-CoV-2 Safety Study for the Treatment of COVID-19

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: DHA Coffee Co., Ltd · Industry
• Sex: All
• Age: 1 Year – 130 Years
• Healthy volunteers: Accepted

Summary

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to protect Telomere chromosomes to maintain Acid Deoxyribonucleic (ADN) Molecules.

Detailed description

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to change and disappear defective cells in virus variants, Covid-19 disease. Pluripotent stem cells produced strong cells serve as a repair system, replacing damaged cells, defective cells and dead cells. CHEMISTRY: SARS-CoV-2 does not use any chemicals, no colors and no additives and no preservatives. Toxicology: SARS-CoV-2 product is not adverse effect, non-toxic and no pharmacal toxicology. SARS-CoV-2 is not placebo drug

Conditions

• SARS-CoV-2

Interventions

Type	Name	Description
DRUG	HIV	Directions: For adults and for Children 1-12 years old. Indication: HIV Ingredient: Organic Rice 93% and Honey 7% Powder (whole) 1g. Masking: None (Open Label) Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date
DRUG	Malignant Neoplasms Safety Study for the Treatment of Neoplasms	Directions: For adults and for Children 1-12 years old. Indication: Malignant Neoplasms . Ingredient: Organic Rice 92% and Honey 8% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date.

Timeline

• Start date: 2025-01-28
• Primary completion: 2025-01-30
• Completion: 2025-02-04
• First posted: 2024-07-08
• Last updated: 2025-09-04